Dr. Abbey Participated in Roundtable Discussion on Newer Therapies for Wet AMD and Diabetic Macular Edema
Texas Retina’s Ashkan Abbey, MD, recently participated in a roundtable discussion on “Navigating Wet AMD and DME Using Newer Therapies” available on Eyetube. Dr. Abbey and fellow panelist Scott Walter, MD, MSc,
read more
Dr. Abbey Presented 2.5 Year Results of the TRUCKEE Study at The Retina Society Annual Meeting
Texas Retina’s Ashkan M. Abbey, MD, presented “The Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study – 2.5 Year Results” at the 57thAnnual Scientific Meeting of
read more
Dr. Abbey and Dr. Callanan Inducted into The Retina Society
Texas Retina’s Ashkan M. Abbey, MD, and retired Texas Retina physician David Callanan, MD, were officially inducted into The Retina Society at the organization’s 57th Annual Scientific Meeting held September 11-15, in
read more
Dr. Abbey Discusses Cataract Surgery in Patients with AMD on New Podcast Episode
Cataracts and age-related macular degeneration (AMD) are two of the most common eye conditions. Texas Retina’s Ashkan Abbey, MD, was recently invited to participate in the latest episode of “Blind Spot –
read more
Dr. Abbey Publishes Case Report on Management of Cystoid Macular Edema in Coats’ Disease
Texas Retina’s Ashkan M. Abbey, MD, recently co-authored a case report in the medical journal Ophthalmic Surgery, Lasers and Imaging Retina (OSLI Retina) on the use of an injectable flucocinolone implant for
read more Dr. Abbey First in the World to Administer Novel Trispecific Fusion Antibody EB-105 for Diabetic Macular Edema as Part of Phase Ib LOTUS Clinical Trial
On July 9, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase Ib LOTUS trial of EB-105, the world’s first pentavalent trispecific
read more
Dr. Abbey Presented Real-world Outcomes of Fluocinolone Acetonide Intravitreal Implant for Non-infectious Uveitis at ASRS 2024 Annual Meeting
Texas Retina’s Ashkan M. Abbey, MD, presented “36-month Optical Coherence Tomography Outcomes from CALM: A Registry Evaluating Treatment of Chronic Non-infectious Uveitis with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant” at the
read more Dr. Abbey Presented Key Results of DAVIO 2 Clinical Trial for Wet AMD at Retina World Congress
At the recently held 2024 Retina World Congress Meeting, Texas Retina’s Dallas Director of Clinical Research Ashkan M. Abbey, MD, presented topline results from the DAVIO 2 clinical trial investigating EYP-1901 (Duravyu),
read more Dr. Abbey Presents GALE Study Data at the Association for Research in Vision and Ophthalmology
At this year’s ARVO 2024, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), Texas Retina’s Dr. Abbey presented 36-month data from the GALE study of pegcetacoplan (brand
read more
Dr. Abbey Recognized as a 2023 Top 10 Reviewer for Ophthalmic Surgery Lasers + Imaging Retina Medical Journal
The medical journal Ophthalmic Surgery Lasers + Imaging Retina (OSLI Retina) recently recognized Texas Retina Associates’ Ashkan M. Abbey, MD as a “2023 Top 10 Reviewer” in recognition of the quantity, quality
read more